HAM
ALXN

Highstreet Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Highstreet Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,194
Closed -$133K – 318
2018
Q1 		$133K Buy
+1,194
New +$143K 0.01% 227
2017
Q1 		– Sell
-2,020
Closed -$247K – 182
2016
Q4 		$247K Buy
+2,020
New +$247K 0.09% 152

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Highstreet Asset Management's ALXN Position: Q2 2018 in Review

Highstreet Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 1,194 shares — an estimated $133K sold.

Highstreet Asset Management first reported a position in ALXN in Q4 2016 and held it in 2 quarters. The position peaked at $247K in Q4 2016. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • Highstreet Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Highstreet Asset Management sold 1,194 Alexion Pharmaceuticals shares in Q2 2018, an estimated $133K.
  • Highstreet Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Highstreet Asset Management's Alexion Pharmaceuticals position peaked at $247K in Q4 2016.
  • 601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Highstreet Asset Management's 13F filing for Q2 2018, filed 10 Aug 2018.